DR 10628
Alternative Names: DR-10628Latest Information Update: 23 Aug 2023
At a glance
- Originator Zhejiang Doer Biologics
- Class Antihyperglycaemics; Fatty acids; Hepatoprotectants; Peptides; Recombinant fusion proteins
- Mechanism of Action Gastric inhibitory polypeptide receptor agonists; Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-alcoholic steatohepatitis; Type 2 diabetes mellitus
Most Recent Events
- 23 Aug 2023 Phase-I clinical trials in Non-alcoholic steatohepatitis in China (Parenteral), prior to August 2023 (Zhejiang Doer Biologics pipeline, August 2023)
- 23 Aug 2023 Phase-I clinical trials in Type 2 diabetes mellitus in China (Parenteral), prior to August 2023 (Zhejiang Doer Biologics pipeline, August 2023)
- 26 May 2022 Preclinical trials in Non-alcoholic steatohepatitis in China (Parenteral) (Zhejiang Doer Biologics pipeline, May 2022)